

February 1, 2024

Contents

| | |
|--------------------------------------|---|
| Clinical Profile Documentation | 2 |
| Problem Groups..... | 2 |
| Additions..... | 2 |
| Problems..... | 2 |
| Additions..... | 2 |
| Lab Analytes & Panels..... | 2 |
| Additions..... | 2 |
| Medications..... | 3 |
| Additions..... | 3 |
| Updates..... | 3 |
| Regimen Library..... | 4 |
| Additions..... | 4 |
| Updates..... | 5 |
| Renames..... | 6 |
| Research..... | 6 |
| Updates..... | 6 |
| Billing & HCPCS Codes | 7 |
| Updates..... | 7 |
| NDC to HCPCS Crosswalk..... | 8 |
| Additions..... | 8 |

Clinical Profile Documentation

Problem Groups

Additions

The **Problems > Add Details** area is updated with applicable documentation points for the following diagnoses.

Malignant PEComa (perivascular epithelioid cell tumor), is now available with the following memberships:

- Malignant perivascular epithelioid cell neoplasm (disorder)
- Perivascular epithelioid cell neoplasm of uncertain behavior (disorder)
- Primary malignant perivascular epithelioid cell neoplasm (disorder)

Problems

Additions

New items are available for documentation in **Problems** and appear in the **Charge Capture Report (CCR)**. Additional ICD-10 codes may be displayed to present the surrounding nodes.

| Problem | ICD-10 Codes |
|--|--|
| Screening for osteoporosis (procedure) | Z13.820 - Encounter for screening for osteoporosis |

Lab Analytes & Panels

Additions

- 7-aminoclonazepam, S/P, quant
- All small particles, UA
- Alpha-hydroxyalprazolam, S/P, quant
- Alpha-hydroxymidazolam, S/P, quant
- Alprazolam, S/P, quant
- Amphetamines confirmation, serum, ng/mL
- Benzodiazepines confirmation panel
- Benzoylecgonine, serum, ng/mL
- Buprenorphine screen, ng/mL
- Butalbital, serum, ng/mL
- Caris assure liquid biopsy
- Cellular cast, UA, /lpf
- Chitotriosidase mutation analysis
- Chlordiazepoxide, S/P, quant
- Clonazepam, S/P, quant
- Cortisol, random draw, ug/dL
- Cortisol, random urine, ug/dL
- Diazepam, S/P, quant
- Diazepam, serum, ng/mL
- DiviTum TKa assay panel
- Fecal fat, split

- Folate, RBC and serum panel
- Glomerular filtration rate (GFR), mL/min
- Hemoglobin solubility w/reflex to hemoglobinopathy fractionation cascade, blood
- Immunofixation, urine, comment
- Lorazepam, S/P, quant
- MDW (monocyte distribution width)
- Methadone screen, ng/mL
- Methamphetamine toxicology comment, serum
- Midazolam, S/P, quant
- Myeloma staging panel, urine 24 hr
- Myeloma staging, urine 24 hr, interpretation
- Norbuprenorphine, serum, ng/mL
- Opiates confirmation, 6-am, serum, ng/mL
- Oxazepam, S/P, quant
- Oxycodone confirmation, serum, ng/mL
- Oxymorphone confirmation, serum, ng/mL
- Pathologist signature, IFE, random urine
- Pathologist signature, IFE, serum
- Pentobarbital, serum, ng/mL
- Phosphatidylethanolamine ab, Iga, APL/units
- Phosphatidylethanolamine ab, IgG, GPL/units
- Phosphatidylethanolamine ab, IgM, MPL/units
- Rapid flu swab
- Rapid strep swab
- RBC, UA, /hpf
- RVP viral PCR panel comment
- Temazepam, S/P, quant
- UPE interpretation, 24hr, urine

Medications

Additions

- AMG 509 invest IV
- ART-123 invest IV
- BMS-986393 invest IV
- CRB-701 invest IV
- FT825 invest IV
- GIM-122 invest IV
- INV-1120 invest Oral
- MBRC-101 invest IV
- SLC-391 invest Oral
- TERN-701 invest Oral
- TTI-101 invest Oral
- V940 (mRNA-4157) invest IM
- XMT-1660 invest IV

Updates

| Medication | Update |
|---------------------|---|
| AMG 193 invest Oral | New form available: 200 mg tablet |
| ART0380 invest Oral | New form available: 50 mg tablet |
| capivasertib Oral | <ul style="list-style-type: none"> • New maximum flat single dose: 400 mg • New instructions: Take on days 1-4, 8-11, 15-18, 22-25 of a 28-day cycle (4 days on, 3 days off). |

| Medication | Update |
|-----------------------|---|
| Miscellaneous drug IV | New dose unit available: units/kg |
| nirogacestat Oral | <ul style="list-style-type: none"> • New maximum flat single dose: 150 mg • New instructions: Take with or without food. |
| repotrectinib Oral | <ul style="list-style-type: none"> • New maximum flat single dose: 160 mg • New default sig available: 160 mg orally as directed • New instructions: Take once daily on days 1-14 then increase to twice daily thereafter. Take with or without food. |
| Toripalimab-tpzi IV | <ul style="list-style-type: none"> • New maximum flat single dose: 450 mg • New default sig available: 0 mg intravenously Piggyback once • New instructions available: In combination with chemotherapy, the recommended dose is 240 mg every 3 weeks. For monotherapy, the recommended dose is 3 mg/kg every 2 weeks. Dilute to a final concentration of 1-3 mg/mL. Mix by gentle inversion; do not shake. Use a polypropylene infusion bag and infusion set with a 0.2 or 0.22 micron in-line filter. First infusion: Administer over at least 60 minutes. Subsequent infusions: If no infusion-related reactions occurred during the first infusion, administer subsequent infusions over 30 minutes. Do not mix or administer with other drugs. |

Regimen Library

Additions

| Regimen Name | Diagnosis |
|---|---|
| Acalabrutinib + Rituximab IV Maintenance Q56D | Lymphoma, Non-Hodgkin (NHL) (Parent) |
| Capivasertib + Fulvestrant + Goserelin Q28D | Breast Cancer |
| Capivasertib + Fulvestrant + Leuprolide Q28D | Breast Cancer |
| Eflornithine Q30D | Brain Tumor (Parent), Neuroblastoma |
| Enfortumab vedotin-ejfv D1,8,22,29 + Pembrolizumab Q42D | Bladder Cancer, Renal Pelvis and Ureter Cancer, Urethral Cancer |
| Iptacopan Q30D | Paroxysmal Nocturnal Hemoglobinuria |
| Osimertinib + Pemetrexed + Carboplatin Q21D | Lung Cancer, Non-small Cell (NSCLC) |

| Regimen Name | Diagnosis |
|--|--------------------------------------|
| Osimertinib + Pemetrexed + Cisplatin Q21D | Lung Cancer, Non-small Cell (NSCLC) |
| Osimertinib + Pemetrexed Q21D Maintenance | Lung Cancer, Non-small Cell (NSCLC) |
| Paclitaxel D1,8,15 + Carboplatin D1,8,15 Q21D fb Cisplatin + XRT Q7D (Cervical) (Part 1 of 2) | Cervical Cancer |
| Paclitaxel D1,8,15 + Carboplatin D1,8,15 Q21D fb Cisplatin + XRT Q7D (Cervical) (Part 2 of 2) | Cervical Cancer |
| Pembrolizumab (Dose Banding) (Q42D) + Paclitaxel (D1,8,15 Q28D) Q84D | Lymphoma, Hodgkin (HL) |
| Pembrolizumab (Dose Banding) + Ifosfamide CIV D2,23 + Carboplatin D2,23 + Etoposide D1-3,22- 24 (ICE) Q42D | Breast Cancer |
| Pembrolizumab (Dose Banding) + Gemcitabine + Carboplatin Q42D | Breast Cancer |
| Pembrolizumab (Dose Banding) + Gemcitabine + Cisplatin Q42D | Lung Cancer, Non-small Cell (NSCLC) |
| Pembrolizumab Q42D (Dose Banding) (Perioperative NSCLC) | Lung Cancer, Non-small Cell (NSCLC) |
| Pembrolizumab (Dose Banding) (Q42D) + Abraxane (D1,8,15 Q28D) Q84D | Breast Cancer |
| Rituximab IV + CHOP + Acalabrutinib Q21D alternating with Rituximab IV + DHAP (Cisplatin) Q21D | Lymphoma, Non-Hodgkin (NHL) (Parent) |
| Zanubrutinib + Obinutuzumab Q28D | Lymphoma, Non-Hodgkin (NHL) (Parent) |
| Zanubrutinib + Obinutuzumab Maintenance Q56D | Lymphoma, Non-Hodgkin (NHL) (Parent) |

Updates

Regimens for the following diagnoses have been updated based on the Collaborative Care Committee voting. Changes include but are not limited to reference update, drug infusion instruction updates, renaming of regimens, premedication template updates and number of cycles.

- All Problems
- Arthritis, Rheumatoid
- Breast Cancer
- Colon Cancer
- Fallopian Tube Cancer
- Lymphoma, Hodgkin (HL)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Ovarian and Primary Peritoneal Cancer
- Pancreatic Cancer
- Penile Cancer
- Rectal Cancer

Renames

| Old Name | New Name |
|----------------------------|------------------------|
| Cyclophosphamide D1 Q21D | Cyclophosphamide Q21D |
| Denosumab (Prolia) Q6Month | Denosumab (Prolia) Q6M |

Research

Updates

| | Updated Reference Information | | | |
|------------|--|---|---|---|
| | Updated Drug Service Order Information | | | |
| | Updated Regimen Instructions | | | |
| | Other Changes | | | |
| USOR 18283 | | | | No longer available: USOR 18283 Avelumab Q14D and USOR 18283 Zimberelimab Q21D |
| USOR 20402 | X | | X | |
| USOR 20412 | X | X | | Now available: USOR 20412 Continued Access Selpercatinib (PO; BID) Q28D |
| USOR 21225 | X | X | | |
| USOR 21320 | X | X | X | |
| USOR 21356 | | | X | |
| USOR 21493 | X | X | X | Now available: USOR 21493 Continued Access Phase Capivasertib Q21D |
| USOR 21536 | X | X | | |
| USOR 22003 | X | | | |
| USOR 22017 | X | X | X | |
| USOR 22049 | | X | | |
| USOR 22056 | X | X | X | |
| USOR 22093 | X | X | X | |
| USOR 22136 | X | | | |
| USOR 22166 | | | | No longer available: USOR 22166 NUV-868 Monotherapy Q28D |

| | Updated Reference Information | | | |
|------------|--|---|---|---|
| | Updated Drug Service Order Information | | | |
| | Updated Regimen Instructions | | | |
| | Other Changes | | | |
| USOR 22167 | X | X | X | |
| USOR 22200 | X | | | |
| USOR 22269 | | | | No longer available: USOR 22269 Pembrolizumab + Paclitaxel + Carboplatin Q21D |
| USOR 23025 | | X | | |
| USOR 23030 | X | | | |
| USOR 23046 | X | X | X | Now available: USOR 23046 Second Course lanalumab (4 doses) Q28D (Retreatment) |
| USOR 23047 | X | | | No longer available: USOR 23047 Crossover Lutetium (177Lu) vipivotide tetraxetan (AAA617) Q42D |
| USOR 23051 | X | X | | |
| USOR 23062 | X | | | |
| USOR 23223 | X | X | X | |

Billing & HCPCS Codes

Updates

| Medication | HCPCS Codes |
|--|--|
| Chikungunya vaccine, live (PF) IM | 90589 per 0.5 mL |
| Eplontersen Subcutaneous Auto-Injector | J3490 per 45 mg |
| Travoprost Intracameral Implant | J3490 per 75 mcg |
| zilucoplan Subcutaneous | J3490 per: <ul style="list-style-type: none"> • 16.6 mg • 23 mg • 32.4 mg |

NDC to HCPCS Crosswalk

Additions

| Medication (Brand) | HCPCS Code | NDC |
|--------------------------|-----------------|---|
| Doxorubicin Liposomal IV | J9999 per 20 mg | <ul style="list-style-type: none">• 00338958102• 00338958101 |